The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study
Open accessAbstract
Purpose: Many patients with high-risk non–muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse. We assessed the efficacy and safety of recombinant adenovirus interferon alfa with Syn3 (rAd–IFNα/Syn3), a replication-deficient recombinant adenovirus gene transfer vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC. Methods: In this open-label, multicenter (n = 13), parallel-arm, phase II study ( ClinicalTrials.gov identifier: NCT01687244), 43 patients with HG BCG-refractory or relapsed NMIBC received intravesical rAd–IFNα/Syn3 (randomly assigned 1:1 to 1 × 10 11 viral particles (vp)/mL or 3 × 10 11 vp/mL). Patients who responded at months 3, 6, and 9 were retreated at months 4, 7, and 10. The primary end point was 12-month HG recurrence-free survival (RFS). All patients who received at least one dose were included in efficacy and safety analyses. Results: Forty patients received rAd–IFNα/Syn3 (1 × 10 11 vp/mL, n = 21; 3 × 10 11 vp/mL, n = 19) between November 5, 2012, and April 8, 2015. Fourteen patients (35.0%; 90% CI, 22.6% to 49.2%) remained free of HG recurrence 12 months after initial treatment. Comparable 12-month HG RFS was noted for both doses. Of these 14 patients, two experienced recurrence at 21 and 28 months, respectively, after treatment initiation, and one died as a result of an upper tract tumor at 17 months without a recurrence. rAd–IFNα/Syn3 was well tolerated; no grade four or five adverse events (AEs) occurred, and no patient discontinued treatment because of an adverse event. The most frequently reported drug-related AEs were micturition urgency (n = 16; 40%), dysuria (n = 16; 40%), fatigue (n = 13; 32.5%), pollakiuria (n = 11; 28%), and hematuria and nocturia (n = 10 each; 25%). Conclusion: rAd—IFNα/Syn3 was well tolerated. It demonstrated promising efficacy for patients with HG NMIBC after BCG therapy who were unable or unwilling to undergo radical cystectomy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interferon-inducible antiviral effectors
Sadler, A. J., & Williams, B. R. G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2314 · Cited by 2,160
Cited by
Babjuk, M., Burger, M., Compérat, E. M., Gontero, P., Mostafid, A. H., Palou, J., van Rhijn, B. W. G., Rouprêt, M., Shariat, S. F., Sylvester, R., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.08.016 · Cited by 1,297
Boorjian, S. A., Alemozaffar, M., Konety, B. R., Shore, N. D., Gomella, L. G., Kamat, A. M., Bivalacqua, T. J., Montgomery, J. S., Lerner, S. P., Busby, J. E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30540-4 · Cited by 480
Self-citationMechanisms of BCG immunotherapy and its outlook for bladder cancer
Pettenati, C., & Ingersoll, M. A. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0055-4 · Cited by 457
Metadata
- Authors
- Shore, N. D., Boorjian, S. A., Canter, D. J., Ogan, K., Karsh, L. I., Downs, T. M., Gomella, L. G., Kamat, A. M., Lotan, Y., Svatek, R. S., Bivalacqua, T. J., Grubb, R. L., Krupski, T. L., Lerner, S. P., Woods, M. E., Inman, B. A., Milowsky, M. I., Boyd, A., Treasure, F. P., Gregory, G., Sawutz, D. G., Yla-Herttuala, S., Parker, N. R., & Dinney, C. P. N.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-10-20
- Volume
- 35
- Issue
- 30
- Pages
- 3410-3416
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2599812325
- Cited by
- 167
- References
- 1
- FWCI
- 15.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. https://app.cochat.ai/papers/10.1200/jco.2017.72.3064
- The paper
- Shore, N. D., Boorjian, S. A., Canter, D. J., Ogan, K., Karsh, L. I., Downs, T. M., Gomella, L. G., Kamat, A. M., Lotan, Y., Svatek, R. S., Bivalacqua, T. J., Grubb, R. L., Krupski, T. L., Lerner, S. P., Woods, M. E., Inman, B. A., Milowsky, M. I., Boyd, A., Treasure, F. P., . . . Dinney, C. P. N. (2017). Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.72.3064
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.